Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 134 clinical trials
None
A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors

dose(RP2D) of XZP-3287 and its efficacy and safety in hormone receptor(HR) positive, human epidermal growth factor receptor 2(HER2) negative advanced breast cancer.

  • 0 views
  • 25 Jan, 2021
  • 1 location
None
Palbociclib Combined With an Aromatase Inhibitor in Breast Cancer

to treat hormone receptor-positive/human epidermal growth factor receptor 2-negative locally advanced breast cancer or metastatic breast cancer. This brings more treatment options for hormone

erbb2
growth factor
palbociclib
epidermal growth factor
aromatase inhibitor
  • 0 views
  • 31 Jul, 2021
  • 3 locations
None
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

locally advanced (unresectable) and/or metastatic human epidermal growth factor receptor 2 (HER2)-expressing cancers. This study will also the evaluate the way the body absorbs, distributes, and

  • 448 views
  • 13 Aug, 2021
  • 19 locations
None
Pyrotinib Plus Thalidomide in Advanced NSCLC Patients Harboring HER2 Exon 20 Insertions

Various driver gene mutations have been identified in lung cancer. Among them, human epidermal growth factor 2 (HER2) was identified in approximately 2% of non-small-cell lung cancers. Pyrotinib

  • 0 views
  • 03 Feb, 2021
  • 1 location
None
A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE ) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer

estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer, who have received prior hormonal therapy and chemotherapy in the

erbb2
estrogen
growth factor
palbociclib
estrogen receptor
  • 2 views
  • 26 Jan, 2021
  • 6 locations
None
Afatinib in Advanced Refractory Urothelial Cancer

chemotherapy. Afatinib dimaleate may turn off the function of the epidermal growth factor (EGF) and human epidermal growth factor receptor 2 (HER2) receptors, which may slow the growth of cancer cells or cause

human epidermal growth factor receptor 2
chemotherapy regimen
cancer
measurable disease
systemic chemotherapy
  • 29 views
  • 07 Oct, 2021
  • 5 locations
None
A Study of Abemaciclib in Indian Women With Advanced Breast Cancer

. Participants must have hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer and must live in India. For each participant, the study could last up to eight

erbb2
growth factor
biological factors
breast cancer
cancer
  • 4 views
  • 14 Nov, 2021
  • 16 locations
None
Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress v 3 and v 5 Integrins.

(r/r) glioblastoma multiforme (GBM) or Human Epidermal growth factor Receptor 2 positive (Her2+) breast cancer that has metastasized to the brain expected to overexpress alpha-v beta 3 (v3) and alpha

bevacizumab
EGFR
HER2
cancer
  • 0 views
  • 11 Nov, 2021
  • 1 location
None
Assessing the Immunogenicity of pING-hHER3FL

protein and will be used in a phase I study as immunotherapeutic agent to target cancers that are known to express the human epidermal growth factor receptor HER3. The human epidermal growth factor

metastasis
liver metastasis
metastatic solid tumor
HER2
EGFR
  • 0 views
  • 24 Sep, 2021
  • 1 location
None
Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive HR-Positive Metastatic Breast Cancer

HR+/HER2+Human epidermal growth factor receptor 2 positive and hormone receptor positivemetastatic breast cancer is a special subtype of HER2+breast cancer. Conventional guidelines recommend

erbb2
growth factor
breast cancer
progesterone
epidermal growth factor receptor
  • 9 views
  • 27 Jan, 2021
  • 2 locations